And 3 months later...
There are plenty of examples of drugs being successful second to market. The point I was making is the expected revenues are much less. Look what 3-months did for PD1 inhibitors. For an already small OV market in melanoma, what do you think a 2nd place OV therapy will generate?
Seems I am doing more research into OV therapies than most of the people here. A lot of hope here - let the data tell the story.
And 3 months later...There are plenty of examples of drugs being...
Add IMU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
7.5¢ |
Change
0.005(7.14%) |
Mkt cap ! $548.9M | |||
| Open | High | Low | Value | Volume |
| 7.1¢ | 7.6¢ | 7.1¢ | $1.896M | 25.79M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 9 | 3194318 | 7.4¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 7.6¢ | 331280 | 7 |
View Market Depth
| Last trade - 16.10pm 10/05/2024 (20 minute delay) ? |
|
|||||
|
Last
7.6¢ |
Change
0.005 ( 6.34 %) |
||||
| Open | High | Low | Volume | ||
| 7.1¢ | 7.6¢ | 7.1¢ | 15199158 | ||
| Last updated 15.59pm 10/05/2024 ? | |||||
| IMU (ASX) Chart |